Insulin-like Growth Factor-binding Protein 2 (IGFBP-2)
Test Catalog Information
| Test Catalog Synonyms | |
| EPIC Synonyms |
SOMATOMEDIN-C Insulin-like Growth Factor Protein 2 SOMATOMEDIN C |
| Cerner Primary Mnemonic | Insulin Like Growth FAC II |
| EPIC Display Name | Insulin-like Growth Factor-binding Protein 2 (IGFBP-2) |
| Allscripts (AEHR) Order Name | Insulin-like Growth Factor Protein 2 |
| Sunrise Clinical Manager (SCM) Order Name | Insulin-like Growth Factor Protein 2 |
| EPIC Inpatient Orderable | Yes |
| EPIC Outpatient Orderable | Yes |
| Cerner Results |
ILGF2X RAM48 |
| Clinical Info |
Insulin-like growth factor II (IGF-II) is a 7.5 kilodalton, 67 amino acid peptide which is thought to mediate some of the actions of growth hormone (GH). IGF-II peptide consists of the A, C, and B chains, and is structurally homologous to IGF-I and proinsulin. IGF-II is secreted by the liver and other tissue and is postulated to have mitogenic and metabolic actions at or near the sites of synthesis; this has been termed the paracrine role of IGF-II. IGF-II also appears in the peripheral circulation, where it circulates primarily in a high molecular weight tertiary complex with IGF-binding protein-3 (IGFBP-3) and acid-labile subunit. A smaller proportion of IGF-II may circulate in association with other IGF-binding proteins. The proportion of unbound IGF-II in the circulation has been estimated at >5%. Plasma levels of IGF-II are dependent upon adequate levels of GH and other factors, including adequate nutrition. |
| Specimen Type |
Blood |
| Container |
Red Top Tube |
| Collection Instructions |
Container/Tube: Serum-Gold Top Specimen: 0.5 mL(min 0.1 mL) |
| Transport Instructions |
Frozen serum |
| Specimen Stability | |
| Methodology |
|
| Days Performed |
Wednesday Morning Report available : 4 days |
| Performing Laboratory |
Labcorp-Esoterix |
| CPT |
83519 |
| PDM |
5913800 |
Desired Epic Build Insulin-like Growth Factor-binding Protein 2 (IGFBP-2)
| Cerner Primary Mnemonic: | Insulin Like Growth FAC II | |||||||||
| PDM | 5913800 | |||||||||
| Informatics - Workgroup | Endocrine | |||||||||
| Synonyms * | SOMATOMEDIN-C Insulin-like Growth Factor Protein 2 SOMATOMEDIN C | |||||||||
| Display Name * | Insulin-like Growth Factor-binding Protein 2 (IGFBP-2) | |||||||||
| Order Entry Specimen Sources * | ||||||||||
| Order Entry Specimen Types |
Blood
| |||||||||
| Specimen Navigator Specimen Types | ||||||||||
| Specimen Navigator Specimen Sources | ||||||||||
| Specimen Navigator Short Name | ||||||||||
| Ordering info (EPIC SmartText) | Insulin-like growth factor II (IGF-II) is a 7.5 kilodalton, 67 amino acid peptide which is thought to mediate some of the actions of growth hormone (GH). IGF-II peptide consists of the A, C, and B chains, and is structurally homologous to IGF-I and proinsulin. IGF-II is secreted by the liver and other tissue and is postulated to have mitogenic and metabolic actions at or near the sites of synthesis; this has been termed the paracrine role of IGF-II. IGF-II also appears in the peripheral circulation, where it circulates primarily in a high molecular weight tertiary complex with IGF-binding protein-3 (IGFBP-3) and acid-labile subunit. A smaller proportion of IGF-II may circulate in association with other IGF-binding proteins. The proportion of unbound IGF-II in the circulation has been estimated at >5%. Plasma levels of IGF-II are dependent upon adequate levels of GH and other factors, including adequate nutrition. The actions of IGF-II are mediated by binding to specific cell surface receptors. The function of the type II IGF receptor is not completely defined. IGF-II binds with lower affinity to the IGF-I type receptors and the insulin receptors. These latter receptors may mediate the mitogenic and metabolic actions of IGF-II. Although its specific physiologic role has not been defined, it has been postulated that the interplay of IGF-I and IGF-II with the different cell surface receptors and circulating binding proteins modulates tissue growth. Normal postnatal plasma IGF-II levels are assumed to be at maximum levels, since administration of GH does not result in increased IGF-II levels (unlike IGF-I levels, which increase). Postnatal plasma IGF-II levels show a moderate age-related increase throughout childhood and puberty, and there is no significant variability during the day. IGF-II levels decrease in GH deficiency and in malnutrition. IGF-II levels may also decrease in acromegaly and during exogenous administration of IGF-I. | |||||||||
| IP Orderable | Yes | |||||||||
| OP Orderable | Yes | |||||||||
|
AOEs * | ||||||||||
| AP AOEs | ||||||||||
| Special History | No | |||||||||
| Build Comments | ||||||||||
| Filter * | ||||||||||
| Procedure Category Change | ||||||||||
Cerner Results
| ||||||||||
Current Actual EPIC Build as of 10/28/2024
| Procedure Id | 167401 | ||||||||||||||||||||||||
| Pdm | 5913800 | ||||||||||||||||||||||||
| Order Display Name | Insulin-like growth factor 2 (IGF-2) | ||||||||||||||||||||||||
| Procedure Name | INSULIN-LIKE GROWTH FACTOR 2 | ||||||||||||||||||||||||
| Procedure Master Number | LAB10002 | ||||||||||||||||||||||||
| Short Procedure Name | INSULIN LIKE 2 | ||||||||||||||||||||||||
| Category Code | 1.0 | ||||||||||||||||||||||||
| Category Code Record Name | LAB BLOOD ORDERABLES | ||||||||||||||||||||||||
| Synonyms | SOMATOMEDIN-C INSULIN-LIKE GROWTH FACTOR PROTEIN 2 SOMATOMEDIN C | ||||||||||||||||||||||||
| Clinically Active | Yes | ||||||||||||||||||||||||
| Orderable | Yes | ||||||||||||||||||||||||
| Performable | Yes | ||||||||||||||||||||||||
| Filter Genomics | |||||||||||||||||||||||||
| Reference Link Url | https://labs.northwell.edu/epic/test/167401 | ||||||||||||||||||||||||
| Ordering Instructions | |||||||||||||||||||||||||
| Default Specimen Type | Blood | ||||||||||||||||||||||||
| Specimen Type Pick List | Blood | ||||||||||||||||||||||||
| Specimen Type List | |||||||||||||||||||||||||
| Op Specimen Type List | |||||||||||||||||||||||||
| Specimen Source Pick List | Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous | ||||||||||||||||||||||||
| Specimen Source Default - Male | Blood, Venous | ||||||||||||||||||||||||
| Specimen Source Default - Female | Blood, Venous | ||||||||||||||||||||||||
| Specimen Source List | |||||||||||||||||||||||||
| Op Specimen Source List | |||||||||||||||||||||||||
| Ip Lab Test Components For Report | |||||||||||||||||||||||||
| Op Lab Test Components For Report | |||||||||||||||||||||||||
| Order Questions | ["3045300170", "3045300171", "3045300173"] | ||||||||||||||||||||||||
| Order Questions Record Name | NH IP HOME COLLECT DATE NH IP HOME COLLECT DAYS NH IP HOME COLLECT MEDICALLY NECESSARY | ||||||||||||||||||||||||
| Inpatient Order Questions | [] | ||||||||||||||||||||||||
| Inpatient Order Questions Record Name | |||||||||||||||||||||||||
| Order Specific Question Override | Yes | ||||||||||||||||||||||||
| Inpatient Question Override | |||||||||||||||||||||||||
| Location Restrict List Ip | |||||||||||||||||||||||||
| Location Restrict List Ip Record Name | |||||||||||||||||||||||||
| Location Restrict List Include Ip | |||||||||||||||||||||||||
| Location Restrict List Op | |||||||||||||||||||||||||
| Location Restrict List Op Record Name | |||||||||||||||||||||||||
| Location Restrict List Includes Op | |||||||||||||||||||||||||
| Edp Amb Order Specific Questions Record Name | |||||||||||||||||||||||||
| Edp Ip Order Specific Questions Record Name | |||||||||||||||||||||||||
| Edp Ip Specimen Source | Blood, Venous Blood, Central Line Blood, Arterial Blood, Capillary | ||||||||||||||||||||||||
| Edp Op Specimen Source | |||||||||||||||||||||||||
| Edp Ip Specimen Type | Blood | ||||||||||||||||||||||||
| Edp Op Specimen Type | |||||||||||||||||||||||||
| Derived Edp Ip Buttons S | Blood, Central Line Blood, Venous Blood, Capillary Blood, Arterial | ||||||||||||||||||||||||
| Derived Edp Ip Buttons T | Blood | ||||||||||||||||||||||||
| Derived Edp Op Buttons S | |||||||||||||||||||||||||
| Derived Edp Op Buttons T | |||||||||||||||||||||||||
| Ip Orderable | 1 | ||||||||||||||||||||||||
| Op Orderable | 1 | ||||||||||||||||||||||||
EPIC OP AOEs
| |||||||||||||||||||||||||
| EPIC IP AOEs | |||||||||||||||||||||||||
EPIC Components (results)
| |||||||||||||||||||||||||